Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)
Abstract
Authors
O. Ghatnekar K. Nørgaard K. Skaltsa